Compare ODD & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ODD | OVID |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.2M | 562.5M |
| IPO Year | 2022 | 2017 |
| Metric | ODD | OVID |
|---|---|---|
| Price | $18.91 | $2.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $15.31 | $5.92 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 11-18-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.12 | N/A |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $9.25 | $1.18 |
| 52 Week High | $60.86 | $3.11 |
| Indicator | ODD | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 39.28 |
| Support Level | $11.71 | $2.38 |
| Resistance Level | $19.87 | $2.79 |
| Average True Range (ATR) | 1.03 | 0.12 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 72.69 | 18.59 |
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage. Geographically, the company generates majority revenue from United states followed by other countries and Israel.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.